Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Steensma, David P  [Clear All Filters]
2024
Steensma DP. Altered Oxidative Phosphorylation Confers Vulnerability on IDH1-Mutant Leukemia Cells: Is This Therapeutically Tractable?. Blood Cancer Discov. 2024:OF1-OF3.
2023
Stahl M, Bewersdorf JPhilipp, Xie Z, Porta MGiovanni D, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023:101128.
Mouhieddine TH, Nzerem C, Redd R, Dunford A, Leventhal M, Sklavenitis-Pistofidis R, Tahri S, El-Khoury H, Steensma DP, Ebert BL, et al. Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma. Cancer Res Commun. 2023.
Bewersdorf JPhilipp, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023:101072.
Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, et al. Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplant Cell Ther. 2023.
2021
Tahri S, Mouhieddine TH, Redd RA, Lampe LM, Nilsson KI, El-Khoury H, Su NKham, Nassar AH, Adib E, Bindra G, et al. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2021.
Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, C Hilton B, Nagata Y, Hamilton BK, Mukherjee S, et al. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021:JCO2002810.
2020
Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermak J, Dinmohamed AG, Eeltink C, Eggmann S, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
Steensma DP, Bolton KL. What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. Blood. 2020.
2019
Steensma DP, Ebert BL. Clonal Hematopoiesis as a Model for Premalignant Changes During Aging. Exp Hematol. 2019.
2016
Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, et al. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016.
2015
Brierley CK, Steensma DP. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?. Curr Opin Hematol. 2015.
Steensma DP. Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clin Proc. 2015;90(7):969-83.